- Home
- UWMC vs NAMS Comparison
UWMC vs NAMS Comparison
Compare UWMC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UWMC | NAMS |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | UWMC | NAMS |
|---|---|---|
| Price | $1.19 | $22.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $6.13 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 10.5M | 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,160,569,000.00 | $22,503,000.00 |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $16.60 | $540.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 46.07 | N/A |
| 52 Week Low | $0.93 | $21.02 |
| 52 Week High | $6.38 | $42.21 |
Technical Indicators
Market Signals| Indicator | UWMC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 39.36 |
| Support Level | $0.93 | $21.02 |
| Resistance Level | $1.55 | $37.29 |
| Average True Range (ATR) | 0.07 | 1.48 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 11.48 | 32.50 |
Price Performance
Historical ComparisonAbout UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.